BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18448268)

  • 1. Primary causes of death after permanent prostate brachytherapy.
    Bittner N; Merrick GS; Galbreath RW; Butler WM; Wallner KE; Allen ZA; Brammer SG; Moyad M
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):433-40. PubMed ID: 18448268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):669-77. PubMed ID: 16682149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):32-43. PubMed ID: 15629591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of body mass index on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen Z; Lief JH; Adamovich E
    Urology; 2005 Jan; 65(1):95-100. PubMed ID: 15667872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.
    Beyer DC; McKeough T; Thomas T
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1299-305. PubMed ID: 15817331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Permanent interstitial brachytherapy in younger patients with clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    Urology; 2004 Oct; 64(4):754-9. PubMed ID: 15491715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cigarette smoking on biochemical outcome after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1056-62. PubMed ID: 15001245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Adamovich E
    W V Med J; 2005; 101(4):168-71. PubMed ID: 16296198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of benefit of pelvic radiation in prostate cancer patients with a high risk of positive pelvic lymph nodes treated with high-dose radiation.
    Vargas CE; Galalae R; Demanes J; Harsolia A; Meldolesi E; Nürnberg N; Schour L; Martinez A
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1474-82. PubMed ID: 15964706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
    Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
    Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone.
    Ragde H; Grado GL; Nadir BS
    Arch Esp Urol; 2001 Sep; 54(7):739-47. PubMed ID: 11692443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci (192)Ir source, and neoadjuvant hormonal manipulation for prostate cancer.
    Izard MA; Haddad RL; Fogarty GB; Rinks A; Dobbins T; Katelaris P
    Int J Radiat Oncol Biol Phys; 2006 Sep; 66(1):38-47. PubMed ID: 16904516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brachytherapy in men aged < or = 54 years with clinically localized prostate cancer.
    Merrick GS; Wallner KE; Butler WM; Galbreath RW; Allen ZA; Adamovich E; True L
    BJU Int; 2006 Aug; 98(2):324-8. PubMed ID: 16879672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer.
    Potters L; Morgenstern C; Calugaru E; Fearn P; Jassal A; Presser J; Mullen E
    J Urol; 2005 May; 173(5):1562-6. PubMed ID: 15821486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of perineural invasion on biochemical progression-free survival after prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Galbreath RW; Allen ZA; Adamovich E
    Urology; 2005 Nov; 66(5):1048-53. PubMed ID: 16286122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term androgen deprivation therapy improves survival in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/mL.
    Berthelet E; Pickles T; Lee KW; Liu M; Truong PT;
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):781-7. PubMed ID: 16199312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival after brachytherapy for clinically localized prostate cancer.
    Moyad MA; Merrick GS; Butler WM; Wallner KE; Galbreath RW; Kurko B; Adamovich E
    Urology; 2005 Dec; 66(6):1150-4. PubMed ID: 16360430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
    Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective comparison of androgen deprivation (AD) vs. no AD among low-risk and intermediate-risk prostate cancer patients treated with brachytherapy, external beam radiotherapy, or radical prostatectomy.
    Ciezki JP; Klein EA; Angermeier K; Ulchaker J; Chehade N; Altman A; Mahadevan A; Reddy CA
    Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1347-50. PubMed ID: 15590163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.